Lancet study rates 21 antidepressants for acute use in major depressive disorder

Lancet study rates 21 antidepressants for acute use in major depressive disorder

February 23 2018 A meta-analysis of data on 21 antidepressants has concluded that all are more...

EMA says no new patients should be started on Esyma for uterine fibroids

EMA says no new patients should be started on Esyma for uterine fibroids

February 13 2018 Doctors should not initiate Esyma (ulipristal acetate) in women with uterine...

New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

February 13 2018 The European Medicines Agency has issued new recommendations regarding use of...

EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

February 12 2018 The European Medicines Agency has updated advice regarding the use of retinoids...

New Drug Safety Update issued on need for contraception with mycophenolate mofetil

New Drug Safety Update issued on need for contraception with mycophenolate mofetil

February 9 2018 The medicines regulator has issued a Drug Safety Update relating to mycophenolate...

  • Lancet study rates 21 antidepressants for acute use in major depressive disorder

    Lancet study rates 21 antidepressants for acute use in major depressive disorder

    Friday, 23 February 2018 10:03
  • EMA says no new patients should be started on Esyma for uterine fibroids

    EMA says no new patients should be started on Esyma for uterine fibroids

    Tuesday, 13 February 2018 12:18
  • New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

    New warnings issued for pregnancy and women using valproate for epilepsy, migraine, or bipolar

    Tuesday, 13 February 2018 12:11
  • EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

    EMA updates recommendations on avoidance of retinoids in pregnancy and effect on mental health

    Monday, 12 February 2018 14:21
  • New Drug Safety Update issued on need for contraception with mycophenolate mofetil

    New Drug Safety Update issued on need for contraception with mycophenolate mofetil

    Friday, 09 February 2018 15:01

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageNovember 28 2017

The medicines regulator has issued four Drug Safety Updates relating to gentamicin, quinine, oral tacrolimus preparations, and anti-epileptic drugs.

The MHRA’s gentamicin DSU advises about possible high levels of histamine being present in several different batches of gentamicin injections from different marketing authorisation holders. The manufacturing process of the active pharmaceutical ingredient gentamicin may include higher levels of histamine as a residual from the manufacturing process.

Health professionals are advised to monitor patients for signs of histamine-related adverse effects, including anaphylaxis-type reactions, hypotensive reactions, or increased heart rate. Caution should be used in treating patients with gentamicin, especially if they are also using other drugs which may stimulate histamine release.

The DSU on quinine is a reminder of the dose-dependent effect prolonging the QT-interval in heart rhythm. It says the drug “should be used with caution in patients with risk factors for QT prolongation or in those with atrioventricular block.”

Prescribers need to consider conditions that may impact on QT prolongation such as cardiac disease or electrolyte balance, atrioventricular block or concomitant use of other drugs which can affect the QT interval. Patients requiring phenobarbital or carbamazepine need close monitoring as serum levels could become toxic.

The third DSU advises that changes between oral tacrolimus preparations need to be managed carefully, as “inadvertent switching between tacrolimus products has been associated with reports of toxicity and graft rejection …  tacrolimus has a narrow therapeutic index, and even minor differences in blood levels have the potential to cause graft rejection reactions or toxicity.”

A DSU on oral tacrolimus was first issued in 2012, but the advisory has been reissued as new oral tacrolimus products have been licensed or are now being launched into the market.

The final DSU from relates to considerations about switching between different manufacturers’ anti-epileptic drugs. Advice issued in 2013 still stands, relating to the three risk-based categories of anti-epileptics and changing the brand/manufacturer. Health professionals are now being advised that they should additionally take into account the patient’s perceptions about switching brands.

Links:
MHRA DSU on gentamicin            
MHRA DSU on quinine sulphate                  
MHRA DSU on tacrolimus            
MHRA DSU on anti-epilepsy drugs

Clinical News

February 23 2018 Health Education England has set out educational content expectations for nursing associates who administer medicines to patients.
February 19 2018 Pharmacists should be receiving educational material this week on a new patient safety campaign from the Centre of Pharmacy Postgraduate Education. Resources have been mailed out ahead...